Neurokinin B receptor antagonism in women with polycystic ovary syndrome: A randomized, placebo-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 11, 2016, Pages 4313-4321

  George, Jyothis T ^a   Kakkar, Rahul ^b   Marshall, Jayne ^b   Scott, Martin L ^b   Finkelman, Richard D ^c,f   Ho, Tony W ^d   Veldhuis, Johannes ^d   Skorupskaite, Karolina ^e   Anderson, Richard A ^e   McIntosh, Stuart ^b,g   Webber, Lorraine ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c AstraZeneca ^*  (United States)

^d Mayo Clinic College of Medicine   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f SHIRE   (United States)

^g Metis Medical   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 4901; LUTEINIZING HORMONE; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; PLACEBO; TESTOSTERONE; UNCLASSIFIED DRUG; 3-((METHYLSULFONYL)AMINO)-2-PHENYL-N-(1-PHENYLPROPYL)QUINOLIN-4-CARBOXAMIDE; AMINOQUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; OVARY POLYCYSTIC DISEASE; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDAL IDEATION; TESTOSTERONE BLOOD LEVEL; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; OUTCOME ASSESSMENT; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOQUINOLINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYCYSTIC OVARY SYNDROME; RECEPTORS, NEUROKININ-3; SULFONAMIDES; TESTOSTERONE; YOUNG ADULT;

EID: 84994899414     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1202     Document Type: Article

References (27)

1. MarchWA,MooreVM,Willson KJ, Phillips DI,NormanRJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.HumReprod. 2010;25:544-551.
2. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685-697.
3. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-4245.
4. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565-4592.
5. Rotterdam ESHRE/ASRM-Sponosred PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81:19-25.
6. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health carerelated economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650-4658.
7. Welt CK, Carmina E. Clinical review: lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab. 2013;98:4629-4638.
8. Rocca ML, Venturella R, Mocciaro R, et al. Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opin Pharmacother. 2015;16:1369-1393.
9. Corbett S, Morin-Papunen L. The polycystic ovary syndrome and recent human evolution. Molec Cell Endocrinol. 2013;373:39-50.
10. Anderson AD, Solorzano CM, McCartney CR. Childhood obesity and its impact on the development of adolescent PCOS. Semin Reprod Med. 2014;32:202-213.
11. Ibanez L, Ong KK, Lopez-Bermejo A, Dunger DB, de Zegher F. Hyperinsulinaemic androgen excess in adolescent girls. Nat Rev Endocrinol. 2014;10:499-508.
12. Marshall JC, Eagleson CA, McCartney CR. Hypothalamic dysfunction. Mole Cell Endocrinol. 2001;183:29-32.
13. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20:485-500.
14. George JT, Seminara SB. Kisspeptin and the hypothalamic control of reproduction: lessons from the human. Endocrinology. 2012; 153:5130-5136.
15. Topaloglu AK, Semple RK. Neurokinin B signalling in the human reproductive axis. Mole Cell Endocrinol. 2011;346:57-64.
16. Young J, George JT, Tello JA, et al. Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications. Neuroendocrinology. 2013;97:193-202.
17. Maeda K, Ohkura S, Uenoyama Y, et al. Neurobiological mechanisms underlying GnRH pulse generation by the hypothalamus. Brain Res. 2010;1364:103-115.
18. Malherbe P, Ballard TM, Ratni H. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005-2010). Expert Opin Ther Pat. 2011;21:637-655.
19. Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study. J Clin Psychopharmacol. 2014;34:199-204.
20. Randolph JF, Jr., Crawford S, Dennerstein L, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab. 2006;91:3034-3040.
21. Liu PY, Keenan DM, Kok P, Padmanabhan V, O'Byrne KT, Veldhuis JD. Sensitivity and specificity of pulse detection using a new deconvolution method.AmJ Physiol Endocrinol Metab. 2009; 297: E538-544.
22. Veldhuis JD, Keenan DM, Pincus SM. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev. 2008;29:823-864.
23. Welt CK. Evaluation of the menstrual cycle and timing of ovulation. Waltham, MA: Uptodate; 2015: http://www.uptodate.com/contents/evaluation-of-the-menstrual-cycle-and-timing-of-ovulation. Accessed December 2015.
24. Herbison AE. Physiology of the adult GnRH neuronal network. In: Plant TM, Zeleznik AJ, eds. Knobil and Neill's Physiology of Reproduction. San Diego: Academic Press;2014:399-467.
25. Jayasena CN, Comninos AN, De Silva A, et al. Effects of neurokinin B administration on reproductive hormone secretion in healthy men and women. J Clin Endocrinol Metab. 2014; 99:E19-27.
26. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.NEngl J Med. 2014;371:119-129.
27. Leiva R, Bouchard T, Boehringer H, Abulla S, Ecochard R. Random serum progesterone threshold to confirm ovulation. Steroids. 2015; 101:125-129.